Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study

In the phase 3 POLLUX study, daratumumab plus lenalidomide and dexamethasone (DRd) significantly reduced the risk of progression/death and induced deeper responses vs. lenalidomide and dexamethasone alone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM). We report a subgroup analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Kenshi, Dimopoulos, Meletios A., Takezako, Naoki, Okamoto, Shinichiro, Shinagawa, Atsushi, Matsumoto, Morio, Kosugi, Hiroshi, Yoon, Sung-Soo, Huang, Shang-Yi, Qin, Xiang, Qi, Ming, Iida, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928154/
https://www.ncbi.nlm.nih.gov/pubmed/29712896
http://dx.doi.org/10.1038/s41408-018-0071-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928154/
https://www.ncbi.nlm.nih.gov/pubmed/29712896
http://dx.doi.org/10.1038/s41408-018-0071-x

Ejemplares similares